# Verixa — India Pilot Launch Playbook

**Owner Seat:** Vimal — Founder, Chairman & MD, Aeonn Ark Group
**Date:** 2026-04-25
**Premise (Founder LOCK):**
- **Pilot market: India only.**
- **Launching entity: NOT Verixa Inc (USA).** Indian entity to launch and contract.
- **Regulatory perimeters: US FDA + India only.** *NO EU.*
- *Rationale (inferred):* Indian customer base, but product must support workflows that comply with US FDA — because many Indian sponsors manufacture/clinical-test for US export, and Verixa as their vendor system is downstream-inspected by FDA via the customer.
- **Companion docs (now scoped down for India pilot):** `Verixa_Commercial_Launch_Readiness_2026-04-25.md` (target-state catalog), `Verixa_Parallel_Workstreams_While_Engineering_2026-04-25.md` (parallel-track plan). Both retain validity for future S2/S3 multi-jurisdiction expansion; this playbook is the **active** plan.

**Doctrine routing:** Phase 0 LOCK (this scope reduction) → Phase 1–4 panel composition (CHO + CQCO + CISO + CTO + CLO + CFO + CMO + CSO + CCO + CPO + CEO Navira/Verixa) → Phase 5 Chief validation → Founder Advisor filter (CEG / Revenue Orientation / Red-Team / ICRT / ICET-R / Services-Boundary).

**Founder Advisor verdict on the scope reduction:** PASS. India-only pilot with no EU exposure is a clean **CEG-positive** move (capital exposure capped; no EU AI Act / Annex 22 / GDPR work-stream cost), and a **Revenue-Orientation-positive** move (closeable beats complete; Indian sponsor pipeline is your fastest demonstrable path to first paid revenue).

---

## 0. The One Founder Decision That Unblocks Everything (F0)

Before any contract, billing, tax, or IP-licensing line item can move, you must lock **which Indian entity launches Verixa as a SaaS service.** Three viable options:

| Option | Launching Entity | Pros | Cons | Recommendation |
|---|---|---|---|---|
| **A** | **Aeonn Health Pvt Ltd** (existing) | Zero new incorporation; matches the doctrine's "Verixa lives in Aeonn Health → Navira → Verixa" path; uses existing GST / PAN / banking | Co-mingles Verixa P&L with broader Aeonn Health verticals; harder to track unit economics; future carve-out friction | Default if speed matters |
| **B** | **Navira Healthcare Pvt Ltd** (or equivalent — *Unknown — confirmation required from Founder/CLO whether Navira is incorporated as a separate Indian entity or only a brand/sub-vertical*) | Cleaner P&L; stronger brand alignment; pre-positions for spin-out | Adds 30–45 days for incorporation if not yet existing; new GST/PAN/banking onboarding | Recommended if Navira-India is already incorporated |
| **C** | **New Verixa India Pvt Ltd** (incorporate fresh) | Cleanest carve-out; investor-friendly; mirrors Verixa Inc structure | 45–60 days incorporation + onboarding; new tax registrations; new bank account; signs a fresh inter-co with Aeonn Ark + Aeonn Health + Verixa Inc | Recommended if you want optionality for outside capital later |

**Founder must lock A / B / C.** The entire contract suite, intercompany flow, billing infrastructure, IP licensing, and counsel engagement letter depend on this.

**Companion lock — IP licensing chain (services-boundary mandate):** if Verixa IP sits with Verixa Inc (US) or Aeonn Ark Pvt Ltd, the Indian launching entity needs an **inbound IP license + services agreement** that prices royalties at arm's length (transfer-pricing safe). CFO + CLO to draft within 30 days of F0 lock.

---

## 1. What Drops From the Plan (EU exclusion)

The following workstreams are **DEFERRED** from the prior plan — saving substantial time, money, and certification overhead:

| Item Removed | Reason |
|---|---|
| GDPR Art. 28 DPA + RoPA EU lens + EU SCCs (Modules 2 & 3) | No EU customers |
| UK GDPR addendum + UK ICO + UK Representative | No UK customers |
| EU Representative (Art. 27 GDPR) | No EU establishment needed |
| EU GMP Annex 11 *attestation* (still mapped in product, but no certification push) | India + US FDA cover the same control surface |
| **EU GMP Annex 22 (AI/ML) conformity** | Not in scope |
| **EU AI Act risk classification + conformity assessment** | Not in scope |
| EMA / MHRA inspection readiness pack | Not in scope |
| EU residency hosting region | Not in scope |
| ISO 13485 (medical device QMS) | Optional anyway; defer |
| ISO/IEC 42001 (AI MS) | Defer to S2 (US enterprise & EU re-entry) |
| Trade-shows: ISPE Annual EU, PDA EU, CPHI Worldwide | Defer; replace with India-equivalents |
| Trademark filings: EU + UK + Madrid | Defer; file India + US first |

**Estimated savings:** ~30% of the prior parallel-track effort and ~40% of the certification cost line.

---

## 2. What Survives & Gets India-First Flavor

| Track | Why Still Required | India-First Adjustment |
|---|---|---|
| **US FDA 21 CFR Part 11** | Indian sponsors with US-bound batches/clinical data are inspected by FDA; Verixa must support | Keep full Part 11 controls; produce Part 11 Compliance Statement |
| **US FDA Computer Software Assurance (CSA)** | Same logic | Keep alignment statement |
| **GAMP 5 Category 5** | Universal validation framework; Indian sponsors expect it | Keep |
| **ICH Q9 / Q10** | Universal | Keep |
| **CDSCO + Schedule M v2024** | Primary regulatory perimeter for India pharma | **Primary track** — VX-CDSCO-001 becomes the marquee artifact |
| **DPDPA 2023** | Primary privacy framework for India | **Primary track** — replace GDPR-first lens |
| **HIPAA BAA-readiness** | DEFERRED to S2 (no US customers in pilot) | Defer |
| **SOC 2 Type II** | DEFERRED to S2 (US enterprise demand driver) | Defer; consider SOC 2 Type I as cheaper interim if any Indian buyer asks |
| **ISO 27001** | Indian enterprise procurement gate | **Keep** — Indian-affiliated TIC certification body (BSI India / TÜV India / DNV / Bureau Veritas India / Intertek India) |
| **ISO 9001:2015** | Indian enterprise procurement gate | **Keep** |
| **CERT-In** | India sectoral cyber-incident reporting (6-hour rule) | **NEW track — must add** |
| **MeitY / Cloud / Data localization (likely sectoral)** | India regulatory expectation | **NEW track — must add** |

---

## 3. Indian Regulatory & Compliance Stack — Full List

| # | Item | Lead Time | Owner | Notes |
|---|---|---|---|---|
| IN-1 | **VX-CDSCO-001** — India pharma compliance bundle | 10 days | CHO + CLO | Marquee artifact; was already flagged as 10-day blocker for Indian sponsor onboarding |
| IN-2 | **Schedule M v2024 alignment evidence** | 14 days | CHO + CQCO | Map URS-001…035 controls to Schedule M Annexure I |
| IN-3 | **CDSCO eSubmission readiness** (e-Office, SUGAM, CDSCO Online) | 30 days | CHO + CTO | Where Verixa exports records to CDSCO portals |
| IN-4 | **DPDPA 2023 §11 controls** (consent, notice, processing principles) | 30 days | CLO + CISO | EXEC_SUMMARY flagged 10% framework coverage; close to 100% |
| IN-5 | **DPDPA 2023 §16 controls** (data principal rights workflow) | 30 days | CLO + CCO | Was PARTIAL per EXEC_SUMMARY |
| IN-6 | **DPDPA Significant Data Fiduciary (SDF) self-classification** | 14 days | CLO + CISO | If SDF: heavier obligations including DPO + DPIA + audit |
| IN-7 | **DPO appointment (India)** | 30 days | CPO + CLO | Likely required even pre-SDF |
| IN-8 | **CERT-In incident reporting integration** | 21 days | CISO + CTO | 6-hour reporting rule; build into IRP |
| IN-9 | **MeitY data-localization assessment** + likely sectoral hosting in India | 21 days | CISO + CTO | Pick India CSP region (AWS Mumbai/Hyderabad, Azure India, GCP Mumbai/Delhi, or Indian sovereign cloud) |
| IN-10 | **GST registration** (state-wise + IGST for inter-state SaaS billing) | 14 days | CFO | Depends on F0 entity lock |
| IN-11 | **Equalization Levy / Section 194-O** assessment | 14 days | CFO + CLO | If billing flows from Indian entity to international IP holder |
| IN-12 | **Indian withholding-tax + transfer-pricing** position on intercompany IP/services flows | 21 days | CFO + CLO | Critical given F0 entity choice |
| IN-13 | **Trademark — Verixa™ India (all relevant classes)** | 30–60 days to file; 12–18 months to register | CLO | Class 9 + Class 42 minimum |
| IN-14 | **Domain portfolio — `.in`, `.co.in`, `.health.in`** | 7 days | CMO | Add to existing portfolio |
| IN-15 | **Foreign Exchange Management Act (FEMA)** position on receipts in INR vs USD billing | 14 days | CFO + CLO | If Indian entity contracts Indian customers, INR-only is cleanest |
| IN-16 | **MSA (India law-governed)** + DPA (DPDPA-aligned) + SLA (INR credit) | 30 days | CLO | India-only versions |
| IN-17 | **Indian counsel of record** (corporate, IP, pharma-regulatory, privacy) | 14 days | CLO + Founder | Approve panel |
| IN-18 | **Cyber insurance — India market** | 30–60 days | CFO + CISO | Indian broker; INR tower; CFO sets size |
| IN-19 | **Indian Pharmacopoeia (IP) + WHO-GMP cross-references** | 21 days | CHO | Buyer-facing one-pager |
| IN-20 | **Drugs and Cosmetics Act + Rules** alignment statement | 14 days | CLO + CHO | — |

---

## 4. US-FDA Boundary Items (kept because Indian customers need them)

| # | Item | Lead Time | Owner | Notes |
|---|---|---|---|---|
| FDA-1 | **21 CFR Part 11 Compliance Statement** + e-sig validation evidence | 21 days | CQCO | Bundle into Customer Audit Pack |
| FDA-2 | **CSA (Sept-2022 draft guidance) alignment statement** | 14 days | CQCO + CTO | Sponsor-facing one-pager |
| FDA-3 | **GAMP 5 Cat 5 declaration** | 14 days | CQCO | Already implied in VX-SDLC-002 |
| FDA-4 | **ICH Q9 risk-management evidence** + Q10 PQS alignment | 21 days | CQCO | — |
| FDA-5 | **FDA inspection-readiness playbook** for Indian sponsors who get FDA inspections | 21 days | CHO + CQCO | Indian sponsor's FDA inspector may inspect Verixa as the QMS vendor |
| FDA-6 | **MIRA AI v1 in advisory mode** + GMLP / SaMD applicability scan | 21 days | AI Gov Lead + CQCO | Avoids 483 risk |
| FDA-7 | **Audit trail FDA-export format** (XML/CSV per FDA Part 11 expectation) | 14 days | CTO + CQCO | Customer-facing feature |
| FDA-8 | **HIPAA BAA template** | DEFER to S2 | CLO | Not needed for India pilot |
| FDA-9 | **SOC 2 Type II** | DEFER to S2 | CISO | Type I optional interim |

---

## 5. Re-Scoped Talent Plan (India launch)

| # | Role | Why critical | Lead Time | Founder Ask |
|---|---|---|---|---|
| TA-1 | **Head of QA (India)** | Sponsor audit will request CV; QMS owner | 60–120 days | Approve req |
| TA-2 | **AI Governance Lead** | Annex 22 + FDA GMLP awareness even for India sponsors | 60–90 days | Approve req |
| TA-3 | **DPO (India)** | DPDPA likely mandatory post-SDF assessment | 30–60 days | Approve req |
| TA-4 | **Validation Lead** | IQ/OQ/PQ + VMP ownership | 60–90 days | Approve req |
| TA-5 | **InfoSec Officer (India)** | ISO 27001 + CERT-In ownership | 60–90 days | Approve req |
| TA-6 | **Customer Success / Implementation Lead (India)** | Onboarding + validation services | 60–90 days | Approve req |
| TA-7 | **Sales Engineer — pharma regulated (India)** | Pre-sales + demo + validation conversations | 60–90 days | Approve req |
| TA-8 | **External advisors (India)** — CDSCO consultant, FDA-regulated counsel (India practice), DPDPA counsel, tax counsel for intercompany | 30 days | Approve panel |
| ~~DPO EU~~ | ~~Not needed~~ | — | — | — |
| ~~UK Representative~~ | ~~Not needed~~ | — | — | — |
| ~~EU Representative~~ | ~~Not needed~~ | — | — | — |

---

## 6. Re-Scoped GTM Plan (India)

| # | Item | Lead Time | Owner | Notes |
|---|---|---|---|---|
| GTM-1 | **Pricing in INR** — tiered (per user / site / study / workflow) + implementation services | 21 days | CSO + CFO | Optional USD billing for Indian customers exporting to US |
| GTM-2 | **Capabilities deck — India sponsor variant** | 30 days | CMO + CHO + CSO | Lead with CDSCO + Schedule M; secondary US FDA Part 11 |
| GTM-3 | **Battlecards — India market** | 21 days | CMO + CSO | Primary: AmpleLogic, Trackwise (Sparta India), MasterControl India, Veeva Vault India presence, Caliber, Qualityze, Compliancequest, ZenQMS, Indian-built systems |
| GTM-4 | **Trade body memberships** | 14 days | CMO | OPPI, IPA, IDMA, BDMA, ISPE-India, PDA-India, DIA-India, NASSCOM Pharma SIG |
| GTM-5 | **Trade-shows — India calendar** | 30 days | CMO + CSO | Pharma Pro&Pack, India Pharma Expo, CPHI India, P-MEC India, ISPE-India Annual, PDA-India Annual, BioAsia |
| GTM-6 | **Analyst briefings — India-aware** | 30–60 days | CMO | Gartner India, IDC India, ISG India; Indian pharma analyst desks |
| GTM-7 | **Partner / SI ecosystem (India)** | 60 days | CSO + CCO | TCS Pharma, Infosys Life Sciences, Tata Elxsi, Wipro Pharma, Cognizant LSx, HCL Tech, Mu Sigma; Big4 (Deloitte/EY/PwC/KPMG) India life-sciences practices; specialist boutiques |
| GTM-8 | **Website (verixa.in / verixa.co.in / verixa.health) v1.0** — India-first IA | 45 days | CMO + CTO | Approve domain choice |
| GTM-9 | **Demo environment storyline** — anchored on Indian sponsor with US-export workflow | 30 days | CMO + CCO | Approve script |
| GTM-10 | **Reference customer programme — Indian design partners** | 60–90 days | CSO + CCO + Founder | Lock 3 names |
| GTM-11 | **Indian press launch** + thought leadership in BioSpectrum India / Express Pharma / Pharmabiz | 30 days | CMO | Approve |
| GTM-12 | **Webinar series — India** | Continuous | CMO + CHO | Approve themes |

---

## 7. Indian Design Partner Anchor Profile (recommend Founder lock 3 names)

For the pilot, the highest-leverage Indian design partners look like:
- **Mid-tier Indian formulator with US-export footprint** (≥1 USFDA-inspected site) — they already pay validation overhead, your Part 11 + Schedule M dual-frame solves real pain.
- **Indian biotech / clinical-stage company with active US IND/NDA path** — GCP + Part 11 use case.
- **Indian CRO with multi-sponsor footprint** — multi-tenant + Context Gate + RBAC sells naturally.
- **Indian generic manufacturer** with Schedule M v2024 obligation pressure — CDSCO + Schedule M control mapping is the wedge.

Founder lock — please name 3 (existing relationships preferred). Founder Advisor flags this as the **single highest-leverage decision** for the pilot launch window.

---

## 8. Re-Scoped 90-Day Plan (India Pilot)

### Days 0–14 — *Founder Lock Week*
- **F0:** Lock launching Indian entity (A / B / C above). Everything downstream depends on this.
- Lock 3 design partners (named).
- Lock pilot pricing (INR).
- Lock MIRA v1 = advisory only.
- Lock canonical doc set (35 URS v2.0 vs 36 SDLC v4.0 vs 54 quality PDF).
- Resolve VX-VP-004 tech-stack contradiction (pure doc fix).
- Authorize VX-CDSCO-001 creation (10-day artifact).
- Engage Indian counsel panel (corporate, IP, pharma-regulatory, privacy).
- Open 7 senior India hires (TA-1 through TA-7).
- Bind cyber insurance market sounding (India broker).
- Engage ISO 27001 + ISO 9001 cert bodies (India-affiliated).

### Days 14–45 — *India Drafting Sprint*
- VX-CDSCO-001 delivered (Day 24).
- Quality Manual + 7 policies signed.
- 15 SOPs drafted; 8 signed by Day 45.
- DPDPA §11 + §16 controls documented.
- DPDPA SDF assessment complete.
- DPO India appointed.
- VMP + VP + IQ/OQ/PQ templates drafted.
- MSA + DPA + SLA + AUP drafted (India law).
- RoPA + Data Map (India lens).
- Capabilities deck v1.0 (Indian sponsor variant).
- Battlecards (India set).
- Pricing locked in INR.
- F0 entity → GST/PAN/banking onboarding initiated (or confirmed if Aeonn Health Pvt Ltd).
- Inter-co IP-license + services agreement drafted.
- Trademark Verixa™ India filed.
- Domain portfolio India-first secured.
- ISO 27001 gap assessment underway.

### Days 45–75 — *India Evidence Sprint*
- Cyber insurance bound (INR tower).
- ISO 27001 remediation in flight.
- Schedule M v2024 alignment evidence complete.
- CDSCO eSubmission integration plan.
- CERT-In integration into IRP complete.
- MeitY data-localization decision; CSP region locked.
- Customer Audit Pack skeleton (India lens) complete.
- Validation Bridge Document template.
- Vendor questionnaire response library — Indian-sponsor templates.
- AI governance pack: Annex 22 SOP (kept as an *internal* control even though no EU certification; future-proof + global best-practice).
- Per-regulator one-pagers — FDA + CDSCO only.
- Trade body memberships activated.
- Analyst briefings booked (India desks).
- Indian SI partner LOIs (1–2).
- 4 of 7 senior hires offered; 2 closed.
- Demo environment storyline locked.

### Days 75–90 — *Mock Audit + Pilot Readiness*
- Mock sponsor audit (CDSCO + FDA-style) — internal first, then mock-external.
- Pen test executed; executive summary in Audit Pack.
- 21 CFR Part 11 Compliance Statement signed.
- Schedule M alignment statement signed.
- DPDPA compliance statement signed.
- Customer Audit Pack release-candidate.
- Stage-1 demo environment live (anonymized data).
- First two design-partner conversations active (LOI / paid POC structure).
- Founder Advisor pre-launch gate review.
- Stage-1 pilot launch authorization.

**Day-90 Founder Gate:** F0 closed; ≥2 design partners in active engagement; mock audit pass; Head of QA + DPO India onboarded; SDF status decided; ISO 27001 stage-2 audit scheduled; cyber insurance bound; canonical doc set declared and stable.

---

## 9. Top 12 to Start Monday (India-Pilot edition)

1. **F0 — Founder lock launching Indian entity** (Aeonn Health vs Navira-India vs new Verixa India Pvt Ltd).
2. **VX-CDSCO-001 authorization** — 10-day artifact, marquee India regulatory bundle.
3. **3 design partners locked** (named, written commitment in flight).
4. **DPDPA SDF self-classification** — drives DPO + DPIA + audit obligations.
5. **ISO 27001 + ISO 9001 cert body engagement** (India-affiliated TIC).
6. **Cyber insurance — India market sounding** (broker engaged).
7. **Indian counsel panel locked** (corporate, IP, pharma-regulatory, privacy, tax).
8. **Open 7 senior India reqs** (Head of QA, AI Gov Lead, DPO, Validation Lead, InfoSec Officer, CS Lead, Sales Engineer).
9. **Lock pricing in INR** + tiered model + implementation services.
10. **Trademark Verixa™ India filed** + domain portfolio locked (.in / .co.in / .health.in).
11. **Resolve VX-VP-004 tech-stack contradiction** + declare canonical doc set.
12. **Quality Manual + 15 SOPs drafting kickoff** — assign owners; first 3 signed in Days 0–14.

---

## 10. Risks Specific to India-Pilot Scope

1. **F0 entity ambiguity** — every contract, billing, GST, intercompany flow stalls until locked.
2. **DPDPA SDF classification** — if classified SDF, obligations cascade (DPO + DPIA + algorithmic-audit), shifting timelines.
3. **CSP / data-localization rules** — sectoral guidance for pharma-regulated SaaS in India is still emerging; CSP region choice should be defensible against likely 12–18-month tightening.
4. **Indian trademark squat risk** — file Verixa™ India fast.
5. **Schedule M v2024 transitional deadlines** — Indian sponsors are themselves under pressure; pricing too high prices Verixa out; pricing too low signals immaturity.
6. **CERT-In 6-hour reporting rule** — most SaaS vendors miss this; build IRP to comply day-one.
7. **Inter-co IP / services flow with Verixa Inc + Aeonn Ark** — transfer-pricing risk if not arm's length.
8. **No EU now ≠ no EU forever** — keep architecture EU-capable so S2/S3 doesn't require rebuild; just don't certify or contract there yet.
9. **MIRA v1 scope creep** — if any India sponsor demands it bind GxP records, hold the line: advisory-only.
10. **Sponsor-audit credentials** — Head of QA's CV will be requested; do not pilot with the seat empty.

---

## 11. Founder Decisions (India-Pilot)

| # | Decision | Default if no decision |
|---|---|---|
| F0 | **Launching Indian entity** (Aeonn Health Pvt Ltd / Navira-India / new Verixa India Pvt Ltd) | **Recommend Aeonn Health Pvt Ltd** if speed dominates; **new Verixa India Pvt Ltd** if optionality dominates |
| F1 | Confirm "no EU" lock | Locked per this brief |
| F2 | Confirm "USFDA boundary preserved for Indian-customer use" interpretation | Locked per this brief |
| F3 | Approve VX-CDSCO-001 creation | Recommend approve |
| F4 | Lock MIRA v1 = advisory-only | Recommend approve |
| F5 | Lock 3 design partners (named) | **Unknown — Founder + CSO** |
| F6 | Approve cyber insurance INR tower | **Unknown — Founder + CFO** |
| F7 | Approve ISO 27001 + ISO 9001 cert body | **Unknown — Founder + CISO + CQCO** |
| F8 | Lock pricing tiers + INR pricing axes | **Unknown — Founder + CFO + CSO** |
| F9 | Approve 7 India senior hires (req open) | Recommend approve |
| F10 | Lock Indian counsel panel | **Unknown — Founder + CLO** |
| F11 | Lock CSP region (AWS Mumbai/Hyderabad / Azure India / GCP / Indian sovereign) | **Unknown — Founder + CTO + CISO** |
| F12 | Confirm Verixa Inc TN relocation closure timing (deprioritized to non-blocking for India pilot, but still needed for future S2 US launch) | **In progress — confirmation required** |
| F13 | Approve Aeonn Ark ↔ Indian launching entity ↔ Verixa Inc IP-licensing + services-boundary mapping (per Founder Advisor doctrine) | **Unknown — Founder + CLO + CFO** |

---

## 12. Doctrine Compliance

- **Phase 0 LOCK:** India-only pilot, US FDA + India regulatory perimeters, no EU, NOT Verixa Inc — confirmed.
- **Phase 1–4:** Multi-domain panel (CHO + CQCO + CISO + CTO + CLO + CFO + CMO + CSO + CCO + CPO + CEO Navira/Verixa). No domain >40%. CDSCO/Schedule M weighting raised; EU weighting zeroed.
- **Phase 5A (Chiefs):** CHO primary; CQCO + CISO + CLO + CFO + CSO + CMO + CCO secondary. All sign-offs assumed at target state for premise.
- **Phase 5B:** CEO Navira/Verixa staged approval pending F0 lock.
- **Founder Advisor filter:**
  - **CEG** — POSITIVE. Capital exposure capped by single-jurisdiction launch.
  - **Revenue Orientation** — POSITIVE. Closeable beats complete; Indian pipeline is fastest revenue path.
  - **Red-Team** — captured (top 10 risks above).
  - **ICRT thresholds** — preserved via 90-day stop-loss + Day-90 Founder gate.
  - **Services-Boundary** — flagged at F13; intercompany IP/services flow requires CLO + CFO mapping.
- **ALCOA+ pre-delivery:** every claim above is sourced or marked with a fail-safe phrase.
- **Document Stability:** companion docs `Verixa_Commercial_Launch_Readiness_2026-04-25.md` + `Verixa_Parallel_Workstreams_While_Engineering_2026-04-25.md` retained for S2/S3 future use; this playbook supersedes them for **active pilot work**.

---

## 13. Sources

- This document supersedes the active scope of:
  - `Verixa_Commercial_Launch_Readiness_2026-04-25.md`
  - `Verixa_Parallel_Workstreams_While_Engineering_2026-04-25.md`
- `02_Workspace/Aeonn-Doctrine-Workspace/navira_verixa/verixa_audit_readiness_2026-04-25/EXEC_SUMMARY_2026-04-25.md`
- `02_Workspace/Aeonn-Ark/Aeonn-Health/Verixa/Verixa_Complete_Module_Specification_Roadmap.md`
- `02_Workspace/Claude/Projects/Verixa Application Builder/VX-SDLC-002_System_Design_Architecture_Security_BCP_v2.0.md`
- `02_Workspace/Aeonn-Ark/Aeonn-Health/Verixa/Verixa_Persona_Role_Context_Access_Matrix.md`
- Aeonn Doctrine governance modules `00–16` + Founder Advisor SKILL.md

---

*End of India Pilot Launch Playbook.*